8 2

()
1. 71
(100) 59
4 9
6 144 2 (
10 3 )
2. 101 3
23

3. 71

4. 101 72

5. 71
5
14

6.

()
1. 101 9 6 195
13 182
101 5 (122 )(58
)(1 ) (1 )

2.

3. 101

4. 101 3 20 21

5. 101 5 11
101 1

6.
101 4 5 8
2,490

()
1. 94-100

35.6%
2. (DOTS)

101 6
6,890
90%

3. X

101 6
2,855 2,031 99 1,797

4. (MDR) 96
5 100
101 6 78
5.

()
1. 101 6 2
3,081 101

1,062 795 74.9%15-24

296 28.8
2.

3.

4.

101 1 6 4 0,275

5.
96
101 46
101 6
7,960


6. 101 6
21 () 928
415 1

101 1 6
23 2,480 311
90%
()
1. 100 266 7,665
100 10 1 101 6 30 258.2
97.86 101
297 5,365 101 10 1
65 6

6
102 1 1 50-64

2. 10-15%

100 12 1 101 3 31

3.
101 1 1 6 30
25 /
7

4.
101

101
8 16 1,247

5. 101 3 1 101 A/H5N1

8 10
9,561
()
1. 101

101 493 5
157

6 111 (70.7%)
2.

WHO 5 5 5
5 ( 5 )

3.
()

4. (Enterobacteriaceae)

5.
101
59 9

()

1. /

2. 101 4
9
MMR
Tdap-IPV

3. 101 5 PCV
4.3
102 2-5 PCV
4. 75

()
1.
100 9 16

3 63
50
4

2. 98
101 6
189 19
81 24
57 112
101 9
101
3.

9 17
24
2 13

10


3
15 21
28 24

()
1.

99 7 1
101 79
203 530

2.

101
39 1311

3.

14

101 6

11

 131 1 3,322
4.

101 16 45
103 1 1
5. 101
10

()
1.
101 14

19,179
5
2.
109
104

96 1 4,131 100
3 6,628 94
71.5% 100 5%
3.

12

100
6.51 16.54

()
1.
101 22
292
101 6 126,271
188,605 1.52
44.21%
2. 97 7 4

99 1,696
95%100 1,211 96.12%
101 6 657 96.65%

99 27 100%100
40 97.5%101

101 6 35
88.57%

13

3. 100 3,507
10 15.1 95 4,406
19.3 899
20.4% 13
2 99 11 100 12

()
1. 101

101 505 238

7

14

2. 101 193
6
5

3. /98
58
4.
1 10

14

2 3

()
1. 5 (33
25100
26)
11

2. 101 1 1 103 12
31
200

15

3. 100

4.

5. ()
1

24

98.7

2
()

()
6.
45
4 5 4 6

5 10

16

1
2

3
4
5
6

3
4 103
5
6
7
8

9
10

17

1 102 1 49
22 55%

10

2 101

3 ()
100 200
101 7 9
101 9 11
101 9 1
4 100 11 1

101 6
22

5 101 7-9

18

7
skill mix

8
101
8 21
9 26

7.
1 101 7 10
() 101

2/3( 60 100 )
101
3 101 2

19


120
6
720
8.
1 101 6 4 6

2 95 100
2,918 ( 1,450 1,468 )

3 100 69
2,488 101 80

4 100

101
101 6 30 747
358 41
12 )9 9 911
440 43
12 416
9.
1 101 7

16

20


101 8
3 17
10
2 102
102
()
1.

2.

1
25
2 101 7 97 6
65 (56
7 1
1 ) 11 21
(
)

21

3. 24
95 3 101 8
3,484,795
4. 15 ( 25 ) CDC
61%
5.
1 101 ()
9 102
2 100 81
10,038
1,288 150
2 101
3 101 ()

11 100 3,286
1,530 11,048

4 101
102 16
5 2,000 (
1,497 227
216 3
)

22

6.

( 12 100 1 101
8 64,528 )
7. (
) ()
() (
)
()
1.
1

100
12 274
2
100
12 208
3
100
12 150
2.

100 12 IC 32

23

3.
101 6
189
175

()
1.
1
HIS
100
48 ( 30 18 )101
7

2 32 ( 23 9 )
(PACS)

3
100 19

101 1-8
4,623
4

24

2.

1 101 1 8 3
15
3
2 101 1 8
314 241
2 40

3.

101
86 1 8
2 9,815 9,535
30,809
1 4,821 875
3 9,579 3,200
4.

5.

25

101
40 26 9
1600
6.

100
776 101 31 ( 27 )
7.

24
101 1 8 201
94.37%
101

8.

9.

26


1 8 29

2 8 29 2
8 30 1
3 8 31
8 31 IDS
9 3
4

5 3,550

()
1.
1

(22 )(63 )(368 )

27


3
5
2.
1
99 100 1
130 25 2
157
99 100
4,550
99 100
5,117 9667
2 ()

101

8
100 101 13

3.
1

97 2.3%98 5.7%99 16.3%

100 21% 101 8 22%

28


100 61,675 97
3.5 101 8 37,622 100
61%
9,443
101 CDR

2 100
100
30 101
4.

7 7 8
7

8 1 2
101 2 23 7 12 9
6 95

5.

29

99

35
2.98%100
( 1 )

100 11

2
(
)
()

100 4
101

30

4
101 7

102 7

6 98 9 101 6
94

266

()
1. 99 4 1
99 3
604 101 6 95
2. ()

31

101 6
6.93
3.

101 6
306 1.19%
4.
7
100 12 1

()
1.
1 100
4.39
4.17 5.01%
4 5,511 4 5,366

32

 145 0.32%
2 101 1 5
4.42
4.14 6.33%
4 5,953 4 5,264
689 1.50%
3

2.

1 100 7 1 7
15 101 1 17 6
1 6 11

3.
1 101

21.47
101 6 20

33


57114C 6

43 12.83
0.572
8.527

9% 4
2 6
3% 9.099

101 1 1
2 101 3.2

3 100 8
RBRVS 37

100 9 100 10

24
101 6 28

34

 101
9 101
12
4.
(1)
(2)
(3)
3

101 6 384.3

()
1.
101 6 280
110
2.
1 101 6
1,927 1.15
7 17.48
1,518 1,165
2 101
101 6
1.37 3.18

35

3.

101 6 2,019
5,692
4.
1

101 6 42.1

18
17.8
17

7.3
2 37

5.
(IDS) 48 (40
)

36

101
25
4-6 (100
4.39 )
()
1.
90

99
150 ()
100 ()
5.7 99 100
32,468 100 12
17 16
6.2
2.

3. 98 12

101 193

37

 46 100
0.15 12.5%
()
1. 100
1 4
100 1 26
1 2

2.

38

3 101 6

1
1
6

101 8 13 2348
( 118 )

()
1. 101 1 6 212
18 1,102
111

2. 101 2 6 4

39

30 1,510
734 609 51 47
47 10 12
16 2 1
1.3%
3.
61 612
4. 101
7 9 102

4 LC/MS/MS

5. 101 1 6 27
()
1.
1 101 8 8 11
17 1 31

40

2 101 1 6
167 )
7 7
73
2.
1 101 6
21 5,220
2 101 6
224
3
101 QSA 9
63.31%101 6
5,521 714 685
17 ()
101 3 20

100

7 1 424

41

101 6

8,375 97.7%

3.
1

http://fadenbook.fda.gov.tw/

101 8 13 435
8,628 101 4
400

2
101
6 28
101 7 9

42

4.
1 101 8 9

8 15

2 101 9 6

101 9 12

101 9 20

3 101 7 21
() ()
8
2

()

43

1. (cGMP) 101 6
160 ( 10 3
) 20 ( 151 ) GMP
40 PIC/S GMP

2. 101 6
685 97 64
3 30 98 64
3 30 10
7 3 480
3. 184
4 5
4. 101
6 52
5. 101 6
449 27
6.
6

7. 101 6 27
GMP
GMP

44

8. 101 4 26 3

9. 101 5 30

10. GMP 16 GMP

11. 20
309 4 PCNB

98.71%
12. 101 8 1

10

13. Wnt

1
2
14. 101 6

45

15.

4 14 5 5

35 4 14 11 30

10

()
1.

101
6 18
4
2.

(REMS)

3. 101 4 5
(REMS) 101 7
REMS 9 12 4
58
4.
4
5.

46

 22 14
31 4
9
6.
71
()
1.
101 6 9,575
83 0.87%

2. 101 6
8,644 100 8,218
5.2%
()
1. 101 6
4,080
1,707.6 99 1
13.9% 101 6 4.08%
2. 99 3
99 1 3
190 216

47

 43 149
21.9%
18.4 %

()

101 6
481
100 3 3
96
101 6
6 6
()
1. 10 1 100
186
94.04% 1 98.35%101
1-5 85 96.35%
99
100

101 4 15
101 1 6 2 8,485

48

2. 101 1 6 2
7,977 768
10 6,842 1,875
4,205 1,674

3. 101 1
6 5,688 340 6,579

4. 100
158 71.4%99
67.2%

100 45.6% (93 24%97

35.1% 2025 50%)

99 11 24

100 5 11
101 6
1,659
99.8%
5.

49


28
4 1

10
50

99 1.090
100 1.079 101 1-6 1.078
16 1.130
18 101 6 101

942
198 293 491
52.12%(491/942)
6. 101 6 193 78
40
101 6
3,560

20

50

101 6
36 9 4,000
101 1-6 291
5
50 100 100
11 101 6
82
244
()
1. 4 5
100 1 12 35 2,375
97.4% 98%
2. 99 100 47
101 3 15 101
1 6 5 6,694
100 3 4 17 9,898
91.38%
97%
3. 5 1 100
30 9,118 101
22 2,659 146

4. 7 7

51


99
103 1 1
98.3%100 100
80%100 1 1 98%
101 1-5 46 7
84.2% 100

5.
22
1
6

14 2 4
45

6.
132 748
383 6,506
13 154

52

 22,475 101

7.
100 2,954
101

101 6 6,598

8. e

100
39 735 101 1 6 13 9,679
3,045
31 Teens
9

1,981
19 87 113
2 6,264
62 51 414 msn
217

53

()
1. 40 64 3 1 55
65 1
101 1 6 112
(100 1 6 )109
2. 100

3 103

6 166 14
416 582
3. 100
18
62.3% 44.6%
4. 100
20 22 7
5 3,843 2
3,958 3 6,418
90%
5. 101
Healthy Lifestyle Healthy Blood Pressure

1,014
887

54


1,987
6. 100-104

101-103

7.

8.
100 536
1,400

9. 483

100 174 101

186 22

10. 100
126 50

33

55


2,881
12 5,305 65
11.

100 9 65
81 101 1 6 50 69
29.8 50-69
62.3 65
269 101 1 5
2,504

12.

100
1,333
477

26%99 100 60%

101 6 22 371
1,333 253 770

80%

56

13. 99

100
100 12
13 101 6 21
101
40

101

101 4 11 20
WHO
Working Group on HPH and Age-Friendly Health
Care

14.

WHO-

100 9

20 101 20

57

APEC 101 8 28-29

2012 APEC

15.

100 12
22 929 3 424
101 6 22 749 3
292

101 12 5
()
1.
Alliance
For Healthy Cities, AFHC
101 6

58

11
AFHC

2 30
2
34
2.
1 101 6 76 WHO

2 100 12
Health Care Without Harm
HCWH
The First Global Climate
and Health Summit HCWH
UNFCCC 17
17
Climate Change and Public Health: Healthy
Climate, Healthy People, Healthy Economy
WHO TF on HPH and
Environment
WHO The First Global

59

Climate and Health Summit

3 100 WHO-HPH Recognition
Project 15
101 6
4 101 4 11-13 20

5 101 21 125

(
)46
40

39

3.
1 101 18 142
( 38.6

2 100 13

60

4. 94

101 28

101 6 19

5.

100 12 7,411
303
6.
1 3,699

101
6
293
2

61


101 6 46
7.
1 101 6
9,345

2 100

8.
100

100 1 1,172
70
604 ( 39.84%)
126

()
1. 22
101 60
600 22

62


101 6
3,310
30 8,000 187
2.
368

3.

0800-367-100

101
-

4.
1 18 99

63

64.1% 100 65.1%

2 100 22
1035
138 101

5.
1

2 101 18 143

()

64

1. 100
99 19.8% 19.1%
99 9.1% 8.2%
2. 101 1 6
34 6,416 2,995
2,939 253 8,000
3. 101

4. 101
113
2012 6
5
5. 101 5
(DG SANCO) Ms. Paola Testori Coggi
37
1

6. 101 3 1

200

65

 101 6 2,054
96%
7.
101 1 6 4 2,828
2012
3 1,067
8. 98 6 4
101 1 6 96
2,551

()
1.

18 96
17.2% 100 11.3%
2. 97 174.4
100 173.7 0.4% 97
10 94.4 100 93.4 1.1%
105 10%
3. 92 96 41%
94 98 43% 2%
58% 60% 2%
4. 101

66

 1 6 279
122.7 38.6
62.3 55.4

2,357 5,836
1,456 868 12,157
664 1,843
5. 101 1
1 3

1 3
HPV101 3 22
6 30 1
2,034 2 2,026
1 1,354 2
1,340
6. 222

69

7.
97 100
39 8

67

101 37
8. 69 101
1 5 8,000 99
1
42%
98 39% 3%

()
1.

101 6 646
30
2.
5
1 4

3.
8
101 6
48 78
17
()
1. DBPR108

68


101 1
FDA 7

2. DBPR104 99
7 30 11 23 FDA

3.
5-MTP

50%

4. 71 101 2
1 2

5. -

69

CKD
2011
10 CKD

6. B

101 4

7. respiratory syncytial
virus, RSV

RSV

8.

70

 Sun1
Sun1
2.5

9.

10.

()
1.
65
(Toward Universal Coverage)

71

 WHA

(2005)

16

10
101 5 24
DG SANCO

(WMA)(WHPA)

2. APEC(2011 2012)APEC (HWG)

(Health
Policy Dialogue) 2012 APEC
(APEC High-Level Meeting on Health
and the Economy)
(A Life Course Approach to Reducing the
Economic Burden of Disease)
Johnson &
Johnson

3. APEC

72

 (Workshop on Cost-effectiveness of
Strategies for Human Security) APEC
101 8
4. 2011

25 40

2012 101 11 14 16

()
1. 101

12

2. Non-communicable
Disesses-Global priorities and solutions

3.
(1)

101 8 7

73

(2)

(TaiwanIHA)(AMDA)
100 8
130
130 101
2
1

(3)

4.
100 6 26

74


101 8 1

SARS

5.
(1)

()
e-Health

(2)

(3)

101 8
179

()
1.
100
23 146

75


101 8 8 50

2.
100 13

()
101 8 52
699

Mr. Bruce Atkinson 5

101/2/15

Pham Van Thuc

101/3/01
6

Mr. Melinda Pavey

101/3/20
5
Esperanza
101/4/9-10
Martinez 2
Dr.

101/4/30
Jewel Mullen 7
Hon.

Jenniffer A. Gonzalez-Colon
101/5/1
6
Excmo. Lic.

101/7/25
Gudy Rivera Estrada 7

Dr. Douglas Slater

101/7/27

76

 Mr. Andreas Wickham

2
(101.0108)

262
50
300
61
19
6
1
52 699

()
1.
1

2
3
4
2.
1

77

3
4
5

()
1. 22 102

2.
3.
1
2
3
4
()
1.
1
2
3

78

2.
1 101

2
3.
1 2

3
4
()
1.
2. 55 64
3.

4.
5.

6.
HPV
7.

79

()
1.
2. CDC
3.
4. Gastein European Health Forum

()

()

()

80


()

96 98
100

()
1.

2.

3.
4.

()

2143

81

 1670

()
1.

2.
3.
4.
5.

()

()
1.

2.

82

 IDS

3. (101-105 )

4.

()
1.

2. 101

()
1. 99 4 1

2.

83

()
1.

6 ()

2.

36

() DRG

1. DRG

2.

84

()

()

102 1 1
6

()
1.
101 3 6 25
7 19

85


2.

3.
10-15
4.
()

()
1.
2.
3.

4.
100%
()
1. 71

86


2. 71

()

()

()

103-104 PCV

()

87

()

()
MIT

()

88

()

1.

2.

()

()

()

()

89

1.

2.
290

3.

4. 101
6

5.
100
101 102
101
102
()

90

()

101

()

()
()

()

()

()

()

91


()

()

()

()
()
()
()
()

92